Clinical and Experimental Sciences University of Southampton Faculty of Medicine Southampton UK.
National Institute for Health and Care Research Southampton Biomedical Research Centre Southampton UK.
Influenza Other Respir Viruses. 2023 Sep 21;17(9):e13188. doi: 10.1111/irv.13188. eCollection 2023 Sep.
Despite the growing recognition of a potentially significant respiratory syncytial virus (RSV) disease burden in adults, relevant evidence in the United Kingdom (UK) is limited. This systematic literature review (SLR) aimed to identify the disease burden of RSV in UK adults, including certain high-risk subgroups and existing evidence gaps. Published studies (2011 onwards) reporting epidemiological, economic and clinical burden outcomes in UK adults (≥15 years) with RSV were identified from indexed databases, including MEDLINE, Embase and the Cochrane library. High-risk groups included elderly (≥65 years), immunocompromised, co-morbid and co-infected patients. Outcomes included RSV incidence/prevalence, mortality, clinical presentation and direct/indirect resource use/costs. Twenty-eight publications on 28 unique studies were identified, mostly in general/respiratory indicator ( = 17), elderly ( = 10) and immunocompromised ( = 6) cohorts. Main outcomes reported in the general/respiratory indicator cohort were RSV infection incidence (seasonal/annual: 0.09-17.9%/6.6-15.1%), mortality (8,482 deaths/season) and direct resource use (including mean general practitioner [GP] episodes/season: 487,247). Seasonal/annual incidence was 14.6-26.5%/0.7-16% in high-risk cohorts. Attributed to RSV in the elderly were 7,915 deaths/season and 175,070 mean GP episodes/season. Only two studies reported on co-morbid cohorts. Clinical burden outcomes were only reported in general and immunocompromised patients, and no evidence was found in any cohort on indirect economic burden or RSV complications. Evidence captured suggests that RSV may have a substantial burden in UK adults. However, available data were limited and highly heterogenous, with further studies needed to characterise the burden of RSV in adults and to validate our findings.
尽管人们越来越认识到呼吸道合胞病毒（RSV）在成年人中可能造成重大疾病负担，但英国（UK）的相关证据有限。本系统文献回顾（SLR）旨在确定 RSV 在英国成年人中的疾病负担，包括某些高危亚组和现有证据空白。从索引数据库（包括 MEDLINE、Embase 和 Cochrane 图书馆）中确定了 2011 年以后发表的报告英国成年人（≥15 岁）中 RSV 的流行病学、经济和临床负担结果的研究。高危人群包括老年人（≥65 岁）、免疫功能低下、合并症和合并感染的患者。结果包括 RSV 发病率/患病率、死亡率、临床表现以及直接/间接资源使用/成本。确定了 28 篇关于 28 项独特研究的出版物，主要在一般/呼吸指标（17 项）、老年人（10 项）和免疫功能低下（6 项）队列中。一般/呼吸指标队列中报告的主要结果是 RSV 感染发病率（季节性/年度：0.09-17.9%/6.6-15.1%）、死亡率（8 例，每季节死亡人数为 8482 人）和直接资源使用（包括每季节平均全科医生[GP]就诊次数：487247 次）。高危人群的季节性/年度发病率为 14.6-26.5%/0.7-16%。老年人归因于 RSV 的死亡人数为 7915 人/每季节和 175070 人/每季节平均 GP 就诊次数。只有两项研究报告了合并症队列。只有一般和免疫功能低下患者报告了临床负担结果，在任何队列中都没有发现间接经济负担或 RSV 并发症的证据。所捕获的证据表明，RSV 可能给英国成年人带来重大负担。然而，现有数据有限且高度异质，需要进一步研究来描述 RSV 在成年人中的负担，并验证我们的研究结果。
